Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study) - PubMed
8 hours ago
- #avelumab
- #urothelial carcinoma
- #hypoalbuminemia
- Hypoalbuminemia was identified as the only independent predictor of poor progression-free survival (PFS) in metastatic urothelial carcinoma (mUC) patients receiving maintenance avelumab therapy after first-line chemotherapy.
- Patients with hypoalbuminemia had significantly shorter median PFS (3.3 months vs. 12.0 months) and overall survival (OS) (9.3 months vs. not reached) compared to those with normal albumin levels.
- The study suggests that preserving nutritional status and avoiding hypoalbuminemia may help optimize the efficacy of maintenance avelumab therapy for mUC.